Feeling Oneself Requires Embodiment: Insights From the Relationship Between Own-Body Transformations, Schizotypal Personality Traits, and Spontaneous Bodily Sensations.

Subtle bodily sensations such as itching or fluttering that occur in the absence of any external trigger (i.e., spontaneous sensations, or SPS) may serve to locate the spatial boundaries of the body.

The wild grape genome sequence provides insights into the transition from dioecy to hermaphroditism during grape domestication.

Background: A key step in domestication of the grapevine was the transition from separate sexes (dioecy) in wild Vitis vinifera ssp. sylvestris (V. sylvestris) to hermaphroditism in cultivated Vitis vinifera ssp.

[Very preterm births in French Polynesia: update and proposal for follow-up].

Introduction: The care of premature infants in French Polynesia is complicated by this country's geographic isolation. We undertook an evaluation of the medical care of very premature infants (VPIs) to find local solutions to this problem.

Objectives: The objectives were to determine the incidence, mortality, and the short- and long-term outcome of very preterm infants in French Polynesia.

The InterPro protein families database: the classification resource after 15 years.

The InterPro database (http://www.ebi.ac.

Respective effects of phlebotomy losses and erythropoietin treatment on the need for blood transfusion in very premature infants.

Background: The benefit to risk ratio of the treatment with erythropoietin (EPO) as a means of limiting the number of transfusions in very preterm infants during hospitalization, seems to be modest since the adoption of restrictive transfusion criteria and of policy limiting phlebotomy losses. We therefore aim to evaluate the factors associated with the number of late blood transfusion in very preterm infants in a unit where the routine use of EPO has been discontinued.

Methods: A comparative "before-after" study was carried out in premature infants born before 32 weeks postmenstrual age (PMA), over a period of one year before (EPO group) and one year after (non-EPO group) the discontinuation of EPO therapy.